Literature DB >> 2469072

Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate.

P Davies1, C L Eaton.   

Abstract

Saturable binding sites for radioiodinated epidermal growth factor (EGF) have been quantified in surgical specimens of benign prostate hypertrophy (BPH), histologically normal (HN) prostate, and prostate cancer. Values for EGF binding did not differ significantly between HN prostate and prostate cancer, although dedifferentiated samples tended to higher levels. These were coincident with lower comparative levels of androgen receptors. Unfractionated BPH tissue contained lower levels of EGF binding than either HN or carcinomatous prostate, but in separated epithelial cells EGF binding fell into the same range. Saturation analyses showed two affinity classes of binding in all except dedifferentiated tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469072     DOI: 10.1002/pros.2990140206

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells.

Authors:  T Turner; P Chen; L J Goodly; A Wells
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

Review 2.  Growth factors as mediators of androgen action during the development of the male urogenital tract.

Authors:  G R Cunha; B Foster; A Thomson; Y Sugimura; N Tanji; M Tsuji; N Terada; P W Finch; A A Donjacour
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

3.  Magmas expression in neoplastic human prostate.

Authors:  Paul T Jubinsky; Mary K Short; George Mutema; Randal E Morris; Georgianne M Ciraolo; Maomi Li
Journal:  J Mol Histol       Date:  2005-02       Impact factor: 2.611

Review 4.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 5.  Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate.

Authors:  E R Sherwood; C Lee
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

6.  GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor.

Authors:  M Rubenstein; M Shaw; P Targonski; C F McKiel; A Dubin; P Guinan
Journal:  Urol Res       Date:  1991

Review 7.  Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer.

Authors:  J L Ware
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

8.  In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals.

Authors:  H Xie; T Turner; M H Wang; R K Singh; G P Siegal; A Wells
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

9.  Epidermal growth factor receptor content in rat prostatic adenocarcinoma: effects of endocrine treatment.

Authors:  J E Damber; A Bergh; B Assarsson; M Gåfvels
Journal:  Urol Res       Date:  1995

10.  Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.

Authors:  E R Sherwood; J L Van Dongen; C G Wood; S Liao; J M Kozlowski; C Lee
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.